TX Austin의 비소세포폐암 임상 시험
비소세포폐암 관련 연구 30개가 Austin 및 인근(약 30마일 이내) 지역에서 참여자를 모집하고 있습니다. 연구 항목을 열어 참여 자격 및 연구 팀 연락처를 확인하세요.
공식 연구 텍스트(영어)
A Study to Evaluate Pumitamig Versus Durvalumab Following Concurrent Chemoradiation Therapy in Participants With Unresectable Stage III Non-small Cell Lung Cancer (NSCLC) (ROSETTA Lung-201)
피험자 모집 중3상
- Texas Oncology-Austin Central, Austin
Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)
피험자 모집 중3상
- Texas Oncology - South Austin, Austin
A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)
피험자 모집 중3상
- Texas Oncology- Central South., Austin
- Texas Oncology Central South, Austin
- Texas Oncology- Central South., Austin
- 외 1개
Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
피험자 모집 중3상
- Texas Oncology - Central/South Texas, Austin
A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
피험자 모집 중2상
- Texas Oncology South, Austin
A Study of ASP546C in Adults With Gastroesophageal Cancer, Pancreatic Cancer or Other Solid Tumors
피험자 모집 중1/2상
- Next Oncology - Austin, Austin
Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer
피험자 모집 중1/2상
- Texas Oncology (Balcones) - SCRI, Austin
Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1
피험자 모집 중3상
- Clinical Study Site, Austin
Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7
피험자 모집 중2/3상
- Local Institution - 007-892-B, Austin
- Local Institution - 007-892-A, Austin
- USOR - Texas Oncology - Dallas Fort Worth (DFW) - South Austin, Austin
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
피험자 모집 중1/2상
- New Experimental Therapeutics - NEXT Oncology, Austin
A Phase 1/1b Study of IAM1363 in HER2 Cancers
피험자 모집 중1상
- NEXT Oncology - Austin, Austin
A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
피험자 모집 중3상
- USO - Texas Oncology, Austin
A Study of a Selective ERBB2 Inhibitor (CGT4255), in Patients With Advanced Solid Tumors
피험자 모집 중1상
- NEXT Oncology Texas, Austin
Phase III Study of Datopotamab Deruxtecan Versus Docetaxel in Previously Treated TROP2-positive Advanced or Metastatic Non-squamous NSCLC Without Actionable Genomic Alterations
피험자 모집 중3상
- Research Site, Austin
Study Evaluating the Safety and Efficacy of HWK-007, a PTK7-directed Antibody Drug Conjugate in Participants With Advanced Solid Tumors
피험자 모집 중1상
- NEXT Oncology - Austin, Austin
Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors
피험자 모집 중1상
- Exelixis Clinical Site #46, Austin
Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
피험자 모집 중1/2상
- Texas Oncology - Central / South Texas, Austin
A Phase 1 Study of PLN-101095 in Adults With Advanced or Metastatic Solid Tumors
피험자 모집 중1상
- NEXT Austin, Austin
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors, Receiving Intravenous Infusion of Azirkitug Alone or in Combination(s) With Budigalimab, Bevacizumab, or Telisotuzumab Adizutecan
피험자 모집 중1상
- NEXT Oncology Austin /ID# 243005, Austin
Study of XB010 in Subjects With Solid Tumors
피험자 모집 중1상
- NEXT Austin, Austin
A Study of IDE034 in Adult Participants With Locally Advanced/Metastatic Solid Tumors Types
피험자 모집 중1상
- NEXT Texas LLC - Austin, Austin
A Study to Investigate the Safety, Pharmacokinetics, and Preliminary Efficacy of IDE574 Therapy in Adult Participants With Advanced Solid Tumors
피험자 모집 중1상
- NEXT Texas LLC - Austin, Austin
Efficacy & Safety of Olvimulogene Nanivacirepvec & Platinum-doublet + Physician's Choice of Immune Checkpoint Inhibitor Compared to Docetaxel in NSCL Cancer
피험자 모집 중2상
- Texas Oncology - Austin Central, Austin
Phase 3 Study of Taletrectinib vs Placebo as an Adjuvant Therapy in ROS1 Positive NSCLC (TRUST-IV)
피험자 모집 중3상
- Sarah Cannon Research Institute (SCRI) - Texas Oncology-Central South, Austin
Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS
피험자 모집 중1/2상
- University of Texas at Austin, Austin
This is a Phase 1 Trial of ZM008, an Anti-LLT1 Antibody, Used as Single Agent Followed by Combination Treatment With Toripalimab in Patients With Advanced Solid Tumors
피험자 모집 중1상
- NEXT Oncology, Austin, TX 78758
A Study of DR-0202 in Patients With Locally Advanced or Metastatic, Relapsed or Refractory Carcinomas
피험자 모집 중1상
- Dren Investigational Site, Austin
A Phase 1/2a Study of DB-1311/BNT324 in Advanced/Metastatic Solid Tumors
피험자 모집 중1/2상
- Research Site 135, Austin
A Study to Assess the Efficacy of WSD0922-FU in Patients With C797S+ Advanced Non-small Cell Lung Cancer
피험자 모집 중2상
- TxO Central/South, Texas Oncology -Central/South Texas, Austin
A Study of OR502, a Monoclonal Antibody Targeting LILRB2, Alone and in Combination With Anticancer Agents
피험자 모집 중1/2상
- NEXT Austin, Austin
다른 도시의 비소세포폐암 시험
- Houston, TX연구 145개
- New York City, NY연구 120개
- Arlington, VA연구 104개
- Nashville, TN연구 96개
- Boston, MA연구 89개
- Los Angeles, CA연구 87개
- St. Louis, MO연구 71개
- Chicago, IL연구 61개
- Baltimore, MD연구 60개
- San Antonio, TX연구 59개
- Columbus, OH연구 55개
- Washington, DC연구 54개
Austin의 다른 연구
- 암 (전체)연구 21개
- 비만연구 20개
- 대장직장암연구 19개
- 전이성 암연구 19개
- 심부전연구 18개
- 과체중연구 18개
- 유방암연구 18개
- 난소암연구 17개
- 자궁내막암연구 16개
- 전립선암연구 15개
- 우울증연구 14개
- 삼중음성 유방암연구 13개
ClinicalTrials.gov 출처, 2026. 10. 1. 기준 데이터입니다. 각 연구는 자체적인 자격 기준을 설정하며, 연구 팀이 참여자를 결정합니다.